ArticleThe Lancet. Rheumatology2021
Type I interferon, anti-interferon antibodies, and COVID-19.
Article in The Lancet. Rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Transfer of IgG from long COVID patients induces symptomology in mice.Cell reports. Medicine · 2026Article
- Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Translating animal models of SARS-CoV-2 infection to vascular, neurological and gastrointestinal manifestations of COVID-19.Disease models & mechanisms · 2025Review
- Toll-like receptor 7 (TLR7)-mediated antiviral response protects mice from lethal SARS-CoV-2 infection.Journal of virology · 2025Article
- Immunopathological syndromes: state of the art.Frontiers in medicine · 2025Review
- Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Review
- Article
- Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors.Immuno-oncology technology · 2023Review
- COVID-19 and systemic lupus erythematosus genetics: A balance between autoimmune disease risk and protection against infection.PLoS genetics · 2022Article
- COVID-19 diverse outcomes: Aggravated reinfection, type I interferons and antibodies.Medical hypotheses · 2022Article
- Resurrecting Epstein-Barr Virus.Pathogens (Basel, Switzerland) · 2022Article
- Early clues regarding the pathogenesis of long-COVID.Trends in immunology · 2022Article
- SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale.International journal of molecular sciences · 2022Review
- T helper type (Th1/Th2) responses to SARS-CoV-2 and influenza A (H1N1) virus: From cytokines produced to immune responses.Transplant immunology · 2022Review
- Low levels ofiScience · 2022Article
- Mechanisms of Immune Dysregulation in COVID-19 Are Different From SARS and MERS: A Perspective in Context of Kawasaki Disease and MIS-C.Frontiers in pediatrics · 2022Review
- AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC.Translational medicine communications · 2022Article
- Endothelial, Immunothrombotic, and Inflammatory Biomarkers in the Risk of Mortality in Critically Ill COVID-19 Patients: The Role of Dexamethasone.Diagnostics (Basel, Switzerland) · 2021Article
- COVID-19 in patients with rheumatic disease: finally, a denominator.The Lancet. Rheumatology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.